Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 2
2007 2
2008 1
2009 3
2010 3
2011 2
2012 2
2013 4
2014 2
2015 7
2016 9
2017 9
2018 8
2019 4
2020 3
2021 4
2022 6
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for lopez tarruella s
Search for Lopez Torruella D instead (2 results)
How we treat HR-positive, HER2-negative early breast cancer.
Lopez-Tarruella S, Echavarria I, Jerez Y, Herrero B, Gamez S, Martin M. Lopez-Tarruella S, et al. Future Oncol. 2022 Mar;18(8):1003-1022. doi: 10.2217/fon-2021-0668. Epub 2022 Jan 31. Future Oncol. 2022. PMID: 35094535 Review.
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S; I-SPY 2 Trial Consortium; Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Yau C, et al. Among authors: lopez tarruella s. Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11. Lancet Oncol. 2022. PMID: 34902335 Free PMC article.
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.
Villacampa G, Tung NM, Pernas S, Paré L, Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, Del Monte-Millán M, Marín-Aguilera M, Brasó-Maristany F, Waks AG, Pascual T, Martínez-Sáez O, Vivancos A, Conte PF, Guarneri V, Vittoria Dieci M, Griguolo G, Cortés J, Llombart-Cussac A, Muñoz M, Vidal M, Adamo B, Wolff AC, DeMichele A, Villagrasa P, Parker JS, Perou CM, Fernandez-Martinez A, Carey LA, Mittendorf EA, Martín M, Prat A, Tolaney SM. Villacampa G, et al. Among authors: lopez tarruella s. Ann Oncol. 2023 Sep;34(9):783-795. doi: 10.1016/j.annonc.2023.05.012. Epub 2023 Jun 9. Ann Oncol. 2023. PMID: 37302750 Free PMC article.
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
Martín M, Carrasco E, Rodríguez-Lescure Á, Andrés R, Servitja S, Antón A, Ruiz-Borrego M, Bermejo B, Guerrero Á, Ramos M, Santaballa A, Muñoz M, Cruz J, Lopez-Tarruella S, Chacón JI, Álvarez I, Martínez P, Miralles JJ, Polonio Ó, Jara C, Aguiar-Bujanda D. Martín M, et al. Among authors: lopez tarruella s. Breast Cancer Res Treat. 2023 Sep;201(2):151-159. doi: 10.1007/s10549-023-07002-1. Epub 2023 Jun 20. Breast Cancer Res Treat. 2023. PMID: 37338729 Free PMC article. Review.
Emerging Therapeutic Options for HER2-Positive Breast Cancer.
Martin M, López-Tarruella S. Martin M, et al. Among authors: lopez tarruella s. Am Soc Clin Oncol Educ Book. 2016;35:e64-70. doi: 10.1200/EDBK_159167. Am Soc Clin Oncol Educ Book. 2016. PMID: 27249772 Free article. Review.
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, Del Monte-Millán M, Massarrah T, Jerez Y, Ayala de la Peña F, García-Sáenz JÁ, Moreno F, Rodríguez-Lescure Á, Malón-Giménez D, Ballesteros García AI, Marín-Aguilera M, Galván P, Brasó-Maristany F, Waks AG, Tolaney SM, Mittendorf EA, Vivancos A, Villagrasa P, Parker JS, Perou CM, Paré L, Villacampa G, Prat A, Martín M. Bueno-Muiño C, et al. Among authors: lopez tarruella s. JAMA Oncol. 2023 Jun 1;9(6):841-846. doi: 10.1001/jamaoncol.2023.0187. JAMA Oncol. 2023. PMID: 37103916 Free PMC article.
Technical Challenges for CTC Implementation in Breast Cancer.
Ramos-Medina R, López-Tarruella S, Del Monte-Millán M, Massarrah T, Martín M. Ramos-Medina R, et al. Among authors: lopez tarruella s. Cancers (Basel). 2021 Sep 15;13(18):4619. doi: 10.3390/cancers13184619. Cancers (Basel). 2021. PMID: 34572846 Free PMC article. Review.
Neratinib (HKI-272) in the treatment of breast cancer.
López-Tarruella S, Jerez Y, Márquez-Rodas I, Martín M. López-Tarruella S, et al. Future Oncol. 2012 Jun;8(6):671-81. doi: 10.2217/fon.12.66. Future Oncol. 2012. PMID: 22764764 Review.
73 results